GlassScriptPhysician profile
April C Palmer
NPI 1104830306
$6,142.47
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,330 · 2020: $1,479 · 2021: $2,053 · 2022: $1,179 · 2023: $85.44 · 2024: $15.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $100.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $857.46 | 2020-2024 | |
| Lilly USA, LLC | $573.94 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $527.83 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $510.11 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $418.01 | 2019-2022 | |
| Novo Nordisk INC | $405.85 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $381.96 | 2019-2022 | |
| Allergan, INC. | $360.47 | 2019-2020 | |
| Amgen INC. | $295.84 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $206.43 | 2019-2021 | |
| Pfizer INC. | $201.64 | 2019-2021 | |
| Amarin Pharma, INC. | $176.38 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $137.42 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.02 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $119.69 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $106.63 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $103.91 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $103.27 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $94.39 | 2020-2021 | |
| Glaxosmithkline, LLC. | $74.83 | 2019-2021 | |
| Abbott Laboratories | $71.45 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $46.73 | 2019 | |
| Upsher-Smith Laboratories LLC | $46.25 | 2020 | |
| Neos Therapeutics, LP | $30.87 | 2019 | |
| Eisai INC. | $24.12 | 2021 | |
| Ibsa Pharma INC. | $23.75 | 2021 | |
| Corium, LLC | $21.14 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.17 | 2021 | |
| Jazz Pharmaceuticals INC. | $18.36 | 2021 | |
| Adlon Therapeutics L.P. | $15.78 | 2020 | |
| Tris Pharma INC | $13.58 | 2021 | |
| Shire North American Group INC | $11.70 | 2019 | |
| Alexion Pharmaceuticals, INC. | $11.49 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Palmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.